vs
AerSale Corp（ASLE）与IOVANCE BIOTHERAPEUTICS, INC.（IOVA）财务数据对比。点击上方公司名可切换其他公司
AerSale Corp的季度营收约是IOVANCE BIOTHERAPEUTICS, INC.的1.0倍（$90.9M vs $86.8M），IOVANCE BIOTHERAPEUTICS, INC.同比增速更快（17.7% vs -4.0%），AerSale Corp自由现金流更多（$9.8M vs $-61.9M），过去两年IOVANCE BIOTHERAPEUTICS, INC.的营收复合增速更高（1001.6% vs 0.2%）
AerSale Corp总部位于美国佛罗里达州多拉市，是一家面向航空领域的全球供应商，主要为客运及货运航空公司、政府机构、跨国整机制造商与独立维修机构提供商用喷气飞机二手整机、发动机、航空耗材，并提供航空工程服务，同时该公司也是飞机机队回收协会的成员企业。
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
ASLE vs IOVA — 直观对比
营收规模更大
ASLE
是对方的1.0倍
$86.8M
营收增速更快
IOVA
高出21.8%
-4.0%
自由现金流更多
ASLE
多$71.7M
$-61.9M
两年增速更快
IOVA
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $90.9M | $86.8M |
| 净利润 | $5.4M | — |
| 毛利率 | 34.1% | 67.4% |
| 营业利润率 | 7.8% | -84.7% |
| 净利率 | 5.9% | — |
| 营收同比 | -4.0% | 17.7% |
| 净利润同比 | 99.7% | — |
| 每股收益（稀释后） | $0.10 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASLEIOVA
| Q4 25 | $90.9M | $86.8M | ||
| Q3 25 | $71.2M | $67.5M | ||
| Q2 25 | $107.4M | $60.0M | ||
| Q1 25 | $65.8M | $49.3M | ||
| Q4 24 | $94.7M | $73.7M | ||
| Q3 24 | $82.7M | $58.6M | ||
| Q2 24 | $77.1M | $31.1M | ||
| Q1 24 | $90.5M | $715.0K |
净利润ASLEIOVA
| Q4 25 | $5.4M | — | ||
| Q3 25 | $-120.0K | $-91.3M | ||
| Q2 25 | $8.6M | $-111.7M | ||
| Q1 25 | $-5.3M | $-116.2M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $509.0K | $-83.5M | ||
| Q2 24 | $-3.6M | $-97.1M | ||
| Q1 24 | $6.3M | $-113.0M |
毛利率ASLEIOVA
| Q4 25 | 34.1% | 67.4% | ||
| Q3 25 | 30.2% | 43.0% | ||
| Q2 25 | 32.9% | 5.5% | ||
| Q1 25 | 27.3% | -0.8% | ||
| Q4 24 | 31.4% | 68.7% | ||
| Q3 24 | 28.6% | 46.2% | ||
| Q2 24 | 28.2% | -0.8% | ||
| Q1 24 | 31.8% | — |
营业利润率ASLEIOVA
| Q4 25 | 7.8% | -84.7% | ||
| Q3 25 | 4.0% | -140.7% | ||
| Q2 25 | 11.7% | -189.8% | ||
| Q1 25 | -10.1% | -245.8% | ||
| Q4 24 | 5.2% | -117.5% | ||
| Q3 24 | 2.4% | -152.1% | ||
| Q2 24 | -2.4% | -327.6% | ||
| Q1 24 | 5.2% | -16464.6% |
净利率ASLEIOVA
| Q4 25 | 5.9% | — | ||
| Q3 25 | -0.2% | -135.3% | ||
| Q2 25 | 8.0% | -186.2% | ||
| Q1 25 | -8.0% | -235.5% | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 0.6% | -142.7% | ||
| Q2 24 | -4.7% | -312.2% | ||
| Q1 24 | 6.9% | -15800.8% |
每股收益（稀释后）ASLEIOVA
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.18 | $-0.33 | ||
| Q1 25 | $-0.10 | $-0.36 | ||
| Q4 24 | $0.05 | $-0.24 | ||
| Q3 24 | $0.01 | $-0.28 | ||
| Q2 24 | $-0.07 | $-0.34 | ||
| Q1 24 | $0.12 | $-0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.4M | $297.0M |
| 总债务越低越好 | $1.3M | — |
| 股东权益账面价值 | $424.4M | $698.6M |
| 总资产 | $640.5M | $913.2M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ASLEIOVA
| Q4 25 | $4.4M | $297.0M | ||
| Q3 25 | $5.3M | $300.8M | ||
| Q2 25 | $5.7M | $301.2M | ||
| Q1 25 | $4.7M | $359.7M | ||
| Q4 24 | $4.7M | $323.8M | ||
| Q3 24 | $9.8M | $397.5M | ||
| Q2 24 | $4.3M | $412.5M | ||
| Q1 24 | $2.6M | $356.2M |
总债务ASLEIOVA
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $907.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
股东权益ASLEIOVA
| Q4 25 | $424.4M | $698.6M | ||
| Q3 25 | $417.1M | $702.3M | ||
| Q2 25 | $415.9M | $698.5M | ||
| Q1 25 | $406.5M | $767.9M | ||
| Q4 24 | $455.6M | $710.4M | ||
| Q3 24 | $451.5M | $773.5M | ||
| Q2 24 | $449.8M | $768.5M | ||
| Q1 24 | $452.0M | $680.0M |
总资产ASLEIOVA
| Q4 25 | $640.5M | $913.2M | ||
| Q3 25 | $646.3M | $904.9M | ||
| Q2 25 | $646.7M | $907.4M | ||
| Q1 25 | $646.1M | $966.7M | ||
| Q4 24 | $604.7M | $910.4M | ||
| Q3 24 | $601.5M | $991.1M | ||
| Q2 24 | $598.7M | $964.3M | ||
| Q1 24 | $571.7M | $869.8M |
负债/权益比ASLEIOVA
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.4M | $-52.6M |
| 自由现金流经营现金流 - 资本支出 | $9.8M | $-61.9M |
| 自由现金流率自由现金流/营收 | 10.8% | -71.3% |
| 资本支出强度资本支出/营收 | 1.7% | 10.7% |
| 现金转化率经营现金流/净利润 | 2.11× | — |
| 过去12个月自由现金流最近4个季度 | $-29.1M | $-336.2M |
8季度趋势，按日历期对齐
经营现金流ASLEIOVA
| Q4 25 | $11.4M | $-52.6M | ||
| Q3 25 | $-8.9M | $-78.7M | ||
| Q2 25 | $19.8M | $-67.4M | ||
| Q1 25 | $-45.2M | $-103.7M | ||
| Q4 24 | $37.5M | $-73.3M | ||
| Q3 24 | $10.4M | $-59.0M | ||
| Q2 24 | $-15.3M | $-98.4M | ||
| Q1 24 | $-21.5M | $-122.3M |
自由现金流ASLEIOVA
| Q4 25 | $9.8M | $-61.9M | ||
| Q3 25 | $-9.8M | $-89.5M | ||
| Q2 25 | $18.6M | $-74.9M | ||
| Q1 25 | $-47.6M | $-109.9M | ||
| Q4 24 | $32.3M | $-77.5M | ||
| Q3 24 | $8.9M | $-61.3M | ||
| Q2 24 | $-18.9M | $-98.9M | ||
| Q1 24 | $-25.0M | $-126.5M |
自由现金流率ASLEIOVA
| Q4 25 | 10.8% | -71.3% | ||
| Q3 25 | -13.8% | -132.7% | ||
| Q2 25 | 17.3% | -124.9% | ||
| Q1 25 | -72.4% | -222.8% | ||
| Q4 24 | 34.0% | -105.1% | ||
| Q3 24 | 10.7% | -104.6% | ||
| Q2 24 | -24.6% | -317.9% | ||
| Q1 24 | -27.7% | -17685.3% |
资本支出强度ASLEIOVA
| Q4 25 | 1.7% | 10.7% | ||
| Q3 25 | 1.3% | 16.1% | ||
| Q2 25 | 1.1% | 12.4% | ||
| Q1 25 | 3.7% | 12.6% | ||
| Q4 24 | 5.6% | 5.7% | ||
| Q3 24 | 1.9% | 3.9% | ||
| Q2 24 | 4.7% | 1.4% | ||
| Q1 24 | 3.9% | 583.4% |
现金转化率ASLEIOVA
| Q4 25 | 2.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
